Dmytro Kharkov

Anika Therapeutics extends implant lifespan with engineered Hyaff for regenerative medicine

Anika Therapeutics extends implant lifespan with engineered Hyaff for regenerative medicine
Anika Therapeutics launches Hyaff scaffold

Anika Therapeutics has introduced Hyaff, an esterified form of hyaluronic acid engineered to last longer in the body.

This extended longevity enables the development of implantable scaffolds that support regenerative medicine and tendon repair, potentially offering longer-lasting clinical benefits for patients. By modifying natural hyaluronic acid, Anika Therapeutics aims to address the challenges of rapid breakdown in biological environments, paving the way for more sustainable and effective therapeutic solutions. Hyaff represents a significant step in the evolution of regenerative technologies, as companies race to develop advanced biomaterials for complex clinical needs.

Anika Therapeutics has previously introduced Hyalofast, a single-stage scaffold for cartilage repair, which also uses Hyaff hyaluronic acid technology. The company has also presented Cingal as the only approved hyaluronic acid and corticosteroid combination therapy for osteoarthritis pain. Both products reflect Anika's ongoing efforts to expand its regenerative medicine and pain management portfolio.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.